SLC5A2 and cardiovascular disorder: The benefits of HbA1c reduction through SGLT2 inhibitors may belarger than we estimated, as evidence shows that SGLT2 inhibitors may provide additionalcardiological protection in addition to HbA1c control.37 However, most of this evidence isfrom people with established cardiovascular disease, which is not the target population ofthis study.